Table 6.
Study | TP | TN | FP | FN | SE (%) | SP (%) | AU (%) | PPV (%) | NPV (%) |
---|---|---|---|---|---|---|---|---|---|
Katki 2011 [10] | 1 226 | 318 093 | 11 415 | 1 084 | 53.12 | 96.51 | 78.41 | 9.72 | 99.71 |
Dillner 2008 [15] | 242 | 22 883 | 1 031 | 139 | 63.51 | 95.72 | 79.61 | 19.01 | 99.42 |
Castle 2012 [16] | 136 | 18 190 | 926 | 260 | 34.32 | 95.22 | 64.72 | 12.81 | 98.61 |
Szarewski 2008 [17] | 256 | 236 | 444 | 17 | 93.81 | 34.72 | 64.22 | 36.61 | 93.32 |
Sørbye 2011 [18] | 48 | 92 | 77 | 8 | 85.71 | 54.42 | 70.12 | 38.41 | 92.02 |
Total | 1 908 | 359 494 | 13 893 | 1 508 | 55.9 | 96.3 | 76.1 | 12.1 | 99.6 |
TP true positive, TN true negative, FP false positive, FN false negative, SE sensitivity, SP specificity, AU = AUROC = accuracy = (SE+SP)/2, PPV positive predictive value, NPV negative predictive value, ASC-US+ = ASC-US, LSIL, ASC-H and HSIL, CIN2+ = CIN2, CIN3 and cancer
1Significantly higher than the average (p<0.05)
2Significantly lower than the average (p<0.05)